Literature DB >> 28340103

Diagnosis-to-ablation time as a predictor of success: early choice for pulmonary vein isolation and long-term outcome in atrial fibrillation: results from the Middelheim-PVI Registry.

Y De Greef1,2, B Schwagten1, G B Chierchia2, C de Asmundis2, D Stockman1, I Buysschaert3.   

Abstract

Aims: The aim of the study is to define long-term outcome of pulmonary vein isolation (PVI) in atrial fibrillation (AF) and to determine whether time window between AF diagnosis and PVI affects outcome. Methods and results: Consecutive AF patients undergoing PVI (2006-14) were followed for 5 years. Primary outcome was clinical success, defined as freedom of documented AF without anti-arrhythmic drugs respecting a 1-month blanking period. A 1000 patients were included (age 60 ± 10 years, CHA2DS2-VASc score 1 ± 1). The cohort was divided in four quartiles (Q) according to the diagnosis-to-ablation time (DAT): Q1 DAT 0-11 months (N = 244), Q2 DAT 12-≤33 months (N = 254), Q3 DAT 34-≤70 months (N = 252) and Q4 DAT 71-360 months (N = 250). Mean follow-up was 44.3±21.0 months. At 5 years, clinical success was achieved in 45.2 ± 2.0% of patients. Independent predictors of clinical success were AF type (HR = 0.61; 95%CI 0.50-0.74; P < 0.0001), left atrial size (HR = 1.03; 95%CI 1.02-1.05; P < 0.0001), DAT (HR = 1.00; 95%CI 1.00-1.00; P = 0.001), ablation technique (P = 0.012), and year of ablation (HR = 0.93; 95%CI 0.86-1.00; P = 0.045) in multivariable-adjusted analysis. The highest clinical success was achieved when PVI was performed within the first year, and gradually declined with increasing DAT: 55.9 ± 4.6% for Q1, 46.9 ± 4.0% for Q2, 45.5 ± 3.6% for Q3, and 35.5 ± 3.6% for Q4 (P < 0.001).
Conclusion: Long-term success rate of PVI is 45.2 ± 2.0%. Shorter diagnosis-to-ablation times are associated with better clinical success. Our data advocate for early PVI following diagnosis of AF.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28340103     DOI: 10.1093/europace/euw426

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  6 in total

1.  Risk-Based Disease Surveillance: The Promise of Early Atrial Fibrillation Identification.

Authors:  Marcie G Berger; David Gutterman
Journal:  Chest       Date:  2019-03       Impact factor: 9.410

2.  Diagnosis-to-Ablation Time and Recurrence of Atrial Fibrillation Following Catheter Ablation: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Derek S Chew; Eric Black-Maier; Zak Loring; Peter A Noseworthy; Douglas L Packer; Derek V Exner; Daniel B Mark; Jonathan P Piccini
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-03-19

3.  Is there a difference in rhythm outcome between patients undergoing first line versus second line paroxysmal atrial fibrillation ablation?

Authors:  Martin Manninger; Jakob Ebner; David Zweiker; Raphael Sieghartsleitner; Bernadette Mastnak; Egbert Bisping; Peter Lercher; Rita Riedlbauer; Brigitte Rotman; Helmut Brussee; Daniel Scherr
Journal:  PLoS One       Date:  2018-12-07       Impact factor: 3.240

4.  Longer diagnosis-to-ablation time is associated with recurrence of atrial fibrillation after catheter ablation-Systematic review and meta-analysis.

Authors:  Raymond Pranata; Veresa Chintya; Sunu B Raharjo; Muhammad Yamin; Yoga Yuniadi
Journal:  J Arrhythm       Date:  2019-12-27

5.  Association of Obesity Measures with Atrial Fibrillation Recurrence After Cryoablation in Patients with Paroxysmal Atrial Fibrillation.

Authors:  Luxiang Shang; Mengjiao Shao; Qilong Guo; Jiasuoer Xiaokereti; Yang Zhao; Yanmei Lu; Ling Zhang; Baopeng Tang; Xianhui Zhou
Journal:  Med Sci Monit       Date:  2020-02-27

6.  Diagnosis-to-ablation time predicts recurrent atrial fibrillation and rehospitalization following catheter ablation.

Authors:  Derek S Chew; Kelley A Jones; Zak Loring; Eric Black-Maier; Peter A Noseworthy; Derek V Exner; Douglas L Packer; Jennifer Grant; Daniel B Mark; Jonathan P Piccini
Journal:  Heart Rhythm O2       Date:  2021-11-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.